Kathy Turner V - 27 Aug 2021 Form 4 Insider Report for IDEXX LABORATORIES INC /DE (IDXX)

Role
Senior Vice President
Signature
/s/ Lily J. Lu, Attorney-in-Fact for Kathy V. Turner
Issuer symbol
IDXX
Transactions as of
27 Aug 2021
Net transactions value
-$1,536,683
Form type
4
Filing time
31 Aug 2021, 17:01:52 UTC
Previous filing
31 Aug 2021
Next filing
02 Sep 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IDXX Common Stock Options Exercise $17,730 +276 +9.6% $64.24* 3,151 27 Aug 2021 Direct F1
transaction IDXX Common Stock Sale $187,128 -276 -8.8% $678.00 2,875 27 Aug 2021 Direct
transaction IDXX Common Stock Options Exercise $178,965 +2,250 +78% $79.54* 5,125 30 Aug 2021 Direct
transaction IDXX Common Stock Sale $685,000 -1,000 -20% $685.00 4,125 30 Aug 2021 Direct
transaction IDXX Common Stock Sale $861,250 -1,250 -30% $689.00 2,875 30 Aug 2021 Direct
holding IDXX Common Stock 100 27 Aug 2021 by spouse F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IDXX Non-Qualified Stock Option (right-to-buy) Options Exercise -276 -100% 0 27 Aug 2021 Common Stock 276 $64.24 Direct F3, F5
transaction IDXX Non-Qualified Stock Option (right-to-buy) Options Exercise -2,250 -23% 7,736 30 Aug 2021 Common Stock 2,250 $79.54 Direct F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes a total of 9.3869 shares acquired under the IDEXX Laboratories, Inc. Employee Stock Purchase Plan on June 30, 2021.
F2 The reporting person disclaims beneficial interest of the shares of common stock held by her spouse except to the extent of her pecuniary interest therein.
F3 Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that became exercisable as to 138 shares in five annual installments beginning June 1, 2015, without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.
F4 Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that became exercisable as to 4,993 shares in five annual installments beginning February 15, 2016, without giving effect to the Stock Split. The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.
F5 Not applicable.